Search Results

Sporos BioDiscovery, Inc. today announced that it will present two posters highlighting preclinical data from the company’s novel TEAD1 / TEAD4 isoform selective inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Sporos BioDiscovery, Inc. today announced the company’s Executive in Residence, Stephen Rubino, Ph.D., will present a company overview on Wednesday, March 15, 2023, at 12:40 p.m. ET at the Oppenheimer 33rd Annual Healthcare Conference, which will take place virtually.

Sporos BioDiscovery, Inc. presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

Sporos BioDiscovery, Inc. today announced that it will present a poster highlighting preclinical data from the company’s novel, isoform selective TEAD inhibitor, SPR1, at the American Association for Cancer Research.

Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to present a groundbreaking update on its latest scientific endeavor:

Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”) today announced its poster presentation highlighting preclinical data on the Company’s lead program, SPR1, a differentiated, novel TEAD inhibitor at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 26-28, 2022, in Barcelona, Spain.

BioDiscovery, Inc. announced that Children’s Hospital of Los Angeles, an award-winning hospital with comprehensive medical care services and programs for children, has signed on as a BioDiscovery Center of Excellence for Clinical Genomics to serve as a reference site for others seeking information and training on BioDiscovery’s NxClinical software.

Latham Biopharm Group (LBG), in collaboration with researchers from RA Capital Management and Nostrum Biodiscovery, recently published a paper in the Journal of Chemical Information and Modeling (JCIM).

Andera Life Sciences, the business line specialising in innovative therapeutics and medical technologies of the asset management company Andera Partners, has announced the finalisation of its fundraising for its BioDiscovery 6 fund at 456 million euros.

BioDiscovery, Inc., a leader in integrated software solutions for genomic data analysis, announced today that PerkinElmer Genomics has selected the company’s NxClinical software as its choice for genomic data analysis for its services.